Pulmonary surfactant full details for md exam answer 10 marks crisp and consise to the point
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, authoritative content from Fishman's and Murray & Nadel's. Let me compile the full 10-mark MD exam answer.
Pulmonary Surfactant
1. Definition
Pulmonary surfactant is a complex mixture of phospholipids and proteins that lines the alveolar air-liquid interface, reducing surface tension and maintaining lung volumes at end expiration. It is essential for normal breathing from birth onwards.
- Fishman's Pulmonary Diseases and Disorders
2. Historical Background
- 1929 - Von Neergaard showed more pressure is needed to inflate an air-filled lung vs. saline-filled lung, suggesting a "retractile surface force."
- 1950s - Clements and Pattle demonstrated the phospholipid component of lung extract lowers alveolar surface tension.
- 1959 - Avery and Mead proved surfactant deficiency in lungs of premature infants dying of neonatal RDS (IRDS).
- Murray & Nadel's Textbook of Respiratory Medicine
3. Composition
| Component | % of Surfactant | Key Role |
|---|---|---|
| Total Lipids | ~90% | Reduce surface tension |
| Dipalmitoylphosphatidylcholine (DPPC) | 50-60% | Primary surface tension-lowering agent |
| Unsaturated phosphatidylcholine | ~20% | Film fluidity |
| Phosphatidylglycerol (PG) | ~10% | Enhances spreading |
| Cholesterol | ~5-8% | Membrane fluidity |
| Surfactant Proteins | ~10% | See below |
Key point: DPPC is unique - both fatty acid side chains are saturated. It is amphiphilic, spontaneously forming a monolayer at air-liquid interfaces.
4. Surfactant Proteins (4 types)
| Protein | Type | Function |
|---|---|---|
| SP-A | Hydrophilic (collectin) | Tubular myelin formation; innate immunity (opsonization, macrophage activation) |
| SP-B | Hydrophobic | Enhances DPPC film spreading; promotes lamellar body formation; stabilizes multilayer lipid films; ESSENTIAL for life |
| SP-C | Hydrophobic | Enhances adsorption and spreading of lipids at air-liquid interface; promotes lipid recycling; encoded by SFTPC gene (chr 8) |
| SP-D | Hydrophilic (collectin) | Innate defense; modulates inflammatory response; surfactant homeostasis |
- SP-B is the only surfactant protein absolutely required for survival - SP-B null infants die of respiratory failure at birth.
- SP-A and SP-B together are required for tubular myelin formation (the major extracellular reservoir of surfactant).
5. Synthesis, Secretion, and Metabolism
Cell of origin: Alveolar Type 2 (AT2) cells (also called type II pneumocytes)
Intracellular pathway:
- Phospholipids + proteins synthesized in ER and Golgi of AT2 cells
- Stored in lamellar bodies (intracellular storage organelles)
- Secreted by exocytosis (stimulated by stretch, beta-agonists, ATP, hyperventilation)
- Lamellar bodies unravel in alveolar hypophase to form tubular myelin (large aggregate surfactant - the most abundant extracellular form)
- Tubular myelin reorganizes into multilayered films at the air-liquid interface
Recycling/Catabolism:
- ~90% of secreted surfactant is recycled by AT2 cells (taken up by endocytosis, reprocessed into lamellar bodies)
- ~10% catabolized by alveolar macrophages (GM-CSF regulated)
- Half-life of surfactant lipids: ~5-10 hours
Stimulants of secretion: Beta-2 agonists, glucocorticoids (antenatal), stretch (breathing), ATP, PGE2
6. Physiological Functions
- Reduces surface tension at air-liquid interface from 70 dyn/cm to near zero - prevents alveolar collapse
- Prevents atelectasis - maintains residual lung volume at end-expiration
- Equalizes pressure across alveoli of different sizes (Laplace's law: P = 2T/r - without surfactant, small alveoli would empty into larger ones)
- Reduces work of breathing - improves lung compliance
- Innate immune defense - SP-A and SP-D opsonize pathogens, activate macrophages; direct antibacterial/antiviral properties
- Mucociliary clearance - alters mucus physical properties; increases ciliary beat frequency
- Anti-inflammatory - suppresses lymphocyte mitogenic responses, scavenges free radicals, reduces oxygen toxicity
7. Developmental Aspects
- Surfactant synthesis begins at ~24-26 weeks gestation
- Adequate surfactant present by ~34-36 weeks gestation
- Glucocorticoids (antenatal betamethasone/dexamethasone) accelerate fetal lung maturity and surfactant production
- Lecithin/sphingomyelin (L/S) ratio in amniotic fluid >2 indicates fetal lung maturity
8. Clinical Correlations
A. Neonatal Respiratory Distress Syndrome (IRDS/HMD)
- Premature infants (<34 weeks) - insufficient surfactant
- Alveolar collapse, hyaline membrane formation, hypoxia
- Rx: Antenatal steroids, exogenous surfactant (intratracheal), CPAP/mechanical ventilation
- Surfactant therapy reduces mortality by 30-40% and reduces complications (pneumothorax, BPD, IVH)
B. ARDS (Adult RDS)
- Plasma proteins inactivate surfactant (fibrinogen, albumin, hemoglobin)
- AT1/AT2 cell death, epithelial barrier dysfunction
- Exogenous surfactant trials in adults showed no mortality benefit
C. Pulmonary Alveolar Proteinosis (PAP)
- Defective GM-CSF signaling → impaired macrophage catabolism of surfactant → accumulation in alveoli
- Most common: autoimmune iPAP (anti-GM-CSF antibodies)
- CT: "crazy paving" pattern
- Rx: Whole lung lavage
D. Genetic Surfactant Disorders
| Gene | Protein | Disease |
|---|---|---|
| SFTPB | SP-B | Lethal neonatal respiratory failure, alveolar proteinosis |
| SFTPC | SP-C | Chronic interstitial lung disease |
| ABCA3 | ATP-binding cassette transporter | Absent lamellar bodies, respiratory failure |
| NKX2-1 | TTF-1 (transcription factor) | Brain-thyroid-lung syndrome |
| CSF2RA/B | GM-CSF receptor | Hereditary PAP |
9. Exogenous Surfactant Preparations
| Type | Source | Examples |
|---|---|---|
| Natural/animal-derived | Bovine lung lavage | Beractant (Survanta), Calfactant (Infasurf) |
| Natural/animal-derived | Porcine lung | Poractant alfa (Curosurf) |
| Synthetic (2nd gen) | Peptide analogues of SP-B/SP-C | In clinical trials |
- Natural surfactants are superior to older synthetic preparations
- Given intratracheally; newer methods include nebulization and thin catheter delivery (LISA/MIST technique)
10. Key Exam Points Summary
- Tubular myelin is the most abundant form of extracellular surfactant; it is the reservoir that feeds the air-liquid interface film
- DPPC is the key surface-active lipid (50-60%)
- SP-B is essential for life; its deficiency causes lethal neonatal respiratory failure
- AT2 cells synthesize and secrete surfactant; AT1 cells cover 95% of alveolar surface area but do not produce surfactant
- Surface tension without surfactant: 70 dyn/cm; with surfactant: reduced to near zero
- L/S ratio >2 = fetal lung maturity
- Antenatal corticosteroids (betamethasone 12 mg x2 doses, 24h apart) given at 24-34 weeks to induce fetal lung maturity
Sources: Fishman's Pulmonary Diseases and Disorders (Ch. 5 - Pulmonary Surfactant and Disorders of Surfactant Homeostasis); Murray & Nadel's Textbook of Respiratory Medicine (Ch. 3 - Pulmonary Surfactant and Alveolar Surface Tension)
This is a shared conversation. Sign in to Orris to start your own chat.